Due to growing evidence suggesting that CDK6 has several pro-tumorigenic functions besides the regulation of the G1-S transition, agents that reduce CDK6 expression are expected to suppress leukemia growth through canonical (kinase-dependent) and non-canonical (kinase-independent) mechanisms. Here, CDK6 is linked to leukemia.